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Summary In order to examine the production of marker proteins, a reproducible method has been estab-
lished for culturing purified epithelial cells from normal and malignant endometrium. We have examined the
differential expression of secretory proteins using immunohistochemistry in frozen tissue sections,
immunocytochemistry in cell cultures derived from the same specimens and protein assays on the culture
supernatants. Placental protein 14 (PP14) was produced by normal premenopausal epithelium but not by the
post-menopausal or malignant endometrial epithelium. In contrast, placental alkaline phosphatase (PLAP) was
produced by endometrial cancers and the endometrial adenocarcinoma-derived cell line Ishikawa, but not by
the normal endometrial epithelium. Other markers such as CA-125, which was produced by both normal and
malignant endometrium but not by the cell line, and human chorionic gonadotrophin (P-hCG), which was
produced by Ishikawa cells but not by any of the fresh tissues, were less cancer specific. Placental alkaline
phosphatase is a direct product of endometrial cancers that can be readily assayed in serum using this two-site
assay to test its clinical usefulness in monitoring patients at risk for endometrial cancer.
Tumour markers for endometrial cancer have received
relatively little attention because of the high rate of early
detection and cure in most women who present with post-
menopausal bleeding. However, interest has been aroused by
the increasing need to monitor women who are receiving
long-term tamoxifen (Uzeily et al., 1993) and those appar-
ently cured of their endometrial cancer, who yet wish to
receive the benefits of hormone replacement therapy (Creas-
man et al., 1991).
Placental protein 14 (PP14) (Bolton et al., 1983) is one of
the major proteins secreted by the normal endometrium and
the decidua in early pregnancy (Bell et al., 1985; Julkunen et
al., 1985). Placental alkaline phosphatase (PLAP), an isoen-
zyme of the alkaline phosphatase group (Fishman et al.,
1968), originally isolated from human trophoblast, is also
expressed in other non-malignant human tissues (Goldstein et
al., 1982; McLaughlin et al., 1984). PLAP is found to be
elevated in the sera of some patients with cancers, parti-
cularly those of the reproductive tract (Nathanson & Fish-
man 1971; Wahren et al., 1979). The beta subunit of human
chorionic gonadotrophin (P-hCG), a normal product of the
trophoblast, and CA-125 (Bast et al., 1981) are both well-
characterised oncofetal antigens (Braunstein, 1983) found to
be synthesised by many normal tissues and epithelial car-
cinomas of the reproductive tract.
We have established an in vitro system for the culture of
normal and malignant endometrial epithelium. The differen-
tial expression of markers has been characterised in frozen
tissue sections, primary cell cultures and in an established
endometrial cell line, in order to demonstrate their specific
production by the cancers as a preliminary to evaluating
their use as clinical markers.
Materials and methods
Tissues
Samples of human endometrium were obtained during nor-
mal non-conceptional menstrual cycles from women undergo-
ing diagnostic curettage for gynaecological investigations. In
the premenopausal tissues the phase of the menstrual cycle
was determined from the last menstrual period and con-
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firmed by histology as being proliferative (n = 10), secretory
(n = 11) or mid-cycle (n = 10). The endometrium was normal
by histological examination, and no other gynaecological
abnormality was present except in three cases of endomet-
riosis and two of cervical carcinoma in situ (CIN III). Five
samples of perimenopausal endometrium with weak pro-
liferative activity (n = 4) or inactive under hormone replace-
ment therapy (n = 1) were obtained from hysterectomies for
fibroids (n = 4) or CIN III (n = 1). Samples from post-
menopausal women were also obtained from patients under-
going hysteroscopy or hysterectomy; two of these were
atrophic, two showed simple hyperplasia and 17 were histo-
logically diagnosed as well-differentiated endometrial
adenocarcinoma. None of these patients was receiving hor-
mone replacement therapy. There was also one sample
derived from a premenopausal patient with well-differentiated
endometrial adenocarcinoma. Hysterectomy specimens were
transported to the pathology laboratory, where a full-
thickness endometrial sample was removed, a small portion
of which was frozen in liquid nitrogen for immunohisto-
chemical analysis and the remainder of which was prepared
for cell culture.
Cell culture
The tissue was trimmed and minced in medium consisting of
a 1:1 mixture of Dulbecco's modified Eagle medium
(DMEM) and Ham's F12, supplemented with 20% heat-
inactivated fetal calf serum and 1% antibiotic/antimycotic
mixture (Gibco, Paisley, UK). The single cells obtained by
mechanical disruption were separated from the clumps by
sedimentation. The supernatant containing the single-cell
suspension was panned in a 50 ml flask (Falcon) for 1 h at
37°C to allow the fibroblast-like cells to attach, and the
floating glandular epithelial cells were then plated in a new
flask at 1 x 106 cells per 5 ml of culture medium. The bigger
clumps that sedimented were digested in a 37°C shaking
waterbath for 1.5 h with collagenase type II 0.05 mgml-',
and DNAse type II 0.05 mg ml-' (Sigma), Dorset, UK).
The tissue was then washed twice in phosphate-buffered
saline (PBS), resuspended in culture medium at 37'C and
panned as above, before culture. The flasks were placed in an
incubator (5% carbon dioxide, 37°C) and were monitored
with daily inspection by microscopy. The culture medium
was changed every 4 days and stored for later analysis at
-200C.
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In order to passage confluent cultures, two different
methods were used:
1. Cells growing in flasks were treated with trypsin/EDTA
solution (0.5 gml-' trypsin, 0.2 g ml-' tetrasodium
EDTA, Sigma) for 10 min or until they detached from the
flask surface. The resulting cell suspension was washed
twice in PBS and plated in new flasks (1 x 106 cells 5 ml-'
per flask.
2. Cells growing in flasks were treated with low-Ca2+
medium (Keratinocyte SFM, Gibco) after 1 week in cul-
ture in order to remove the fibroblast-like cells. The cells
were incubated with low-Ca2+ medium overnight, and the
next morning the medium was replaced with fresh growth
medium. The same treatment was repeated if necessary
after 2-4 days.
The Ishikawa cell line, derived from an endometrial car-
cinoma (Nishida et al., 1985), was a gift from J. White,
Department of Reproductive Physiology, The Hammersmith
Hospital, London, UK. The cells were cultured under the
conditions described above.
Immunohistocytochemistry
The fresh biopsies were cut into 3 mm cubes and frozen in
liquid nitrogen. Sections 7gm thick were cut at - 28°C.
The cells were prepared for staining using two different
methods:
1. Cells in suspension were cytocentrifuged (600g, for
10min) onto slides (5 x I04 cells per slide).
2. Cells were cultured in slide wells for 48 h and washed with
PBS.
All slides were stored at -70°C. Before the staining, all
slides were air dried at room temperature overnight, fixed in
acetone for 15 min and air dried again. A peroxidase-
antiperoxidase detection (PAP) staining method was em-
ployed.
The primary antibodies used were as follows: mouse
monoclonal anti-cytokeratin (high molecular weight, LP34;
and low molecular weight, CAM 5.2), used as undiluted
supernatant (gift from I. Leigh, Department of Experimental
Dermatology, The Royal London Hospital, London, UK);
mouse monoclonals F15; an anti-Thy-l (a non-epithelial cell-
surface glycoprotein) antibody (J. Fabre, Blonde McIndoe
Centre, East Grenstead, UK) diluted 1:200; anti-human
PLAP H17E2 (Travers & Bodmer, 1984); rabbit anti-p-hCG
(Dako, UK) diluted 1:100; and rabbit polyclonal serum
raised against human PP14, diluted 1:1,000 in 20% normal
swine serum PBS (Howell et al., 1989). As a negative control,
the primary antibody was replaced with PBS on one section
from each slide.
Assays
Samples from the culture supernatants from the fourth day
of the culture were assayed as follows: PP14 was measured
using a radioimmunoassay described by Howell et al. (1989).
PLAP was measured by a new two-site radioimmunometric
assay (Iles et al., 1994). The total P-hCG was measured by a
polyclonal radioimmunoassay as described by Iles et al.
(1989). CA-125 was measured using a commercial




In the 13 normal tissues examined there was uniform positive
cytokeratin staining throughout the epithelial glands (Figure
1). In the malignant tissues the glandular elements, while
disorganised, were still morphologically recognisable and
cytokeratin positive (Figure 2) with stronger and more
uniform staining on the malignant epithelium by CAM 5.2
than LP34.
Figure 1 Normal secretory endometrial section stained for
cytokeratins with LP34. All glandular cells appear uniformly
positive surrounded by completely negative stromal cells
(bar = 300jim).
Figure 2 Endometrial adenocarcinoma section stained for
cytokeratins CAM 5.2. Positively stained disorganised glandular
structure connected with cytokeratin-negative stromal tissue
(bar = 30jim).
PP14 was present on the luminal surface of some of the
glands of normal secretory tissues but not in any of the
malignant ones (Figure 3). Occasional weakly PLAP-positive
staining was detected in the lumen of glands from one
(premenopausal with CIN III) of the four normal tissues
examined (two pre-, one peri- and one post-menopausal). In
contrast, strong staining was detected in glandular cells from
five out of eight malignant tissues (Figure 4) and in one
hyperplastic tissue as well. No detectable P-hCG expression
was found in any of the tissues examined.
Primary cell culture
During the development of the method described above, we
established viable cultures forming cell monolayers for 2-3
weeks in 42/58 attempts (Table I). Cells from all stages of the
menstrual cycle have been successfully cultured, and also
from hyperplastic and malignant tissues. No correlation was
found between the stage of the cycle or the age of the patient
and the growth potential or the survival of the cells in
culture.
The relatively low percentage of stromal cells and the lack
of an organised structure in the cancers made it considerably
easier to derive cell suspensions from them, while with the
normal tissues, even with extensive chopping and enzymatic
digestion, there were still many cells in small tightly knit
clumps which would attach, spread and grow in culture.
Increasing enzymatic digestion to 2 h or more failed to
release more cells and reduced their viability. The addition of1012 E. CHATZAKI et al.
Table I Number of endometrial tissues that resulted in viable
monolayers containing epithelial cells cultured in vitro
Type of tissue Successful cultures Total %
Non-malignant
Proliferative 7 10 70
Mid-cycle 6 10 60
Secretory 6 11 54
Hyperplasia 2 2 100
Perimenopausal 4 5 80
Post-menopausal 2 2 100
Total 27 40 67
Malignant
Premenopausal 1 1 100
Post-menopausal 14 17 82
Total 15 18 84
Figure 3 Normal secretory endometrial section stained with
anti-PP14 polyclonal serum, demonstrating the apical nature of
PP14 expression (bar= 20 lgm).
Figure 4 Endometrial adenocarcinoma section stained for PLAP
with H17E2. PLAP appears to be expressed throughout the
glandular structure, but not in the intervening band of stromal
tissue (bar = 20gAm).
epidermal growth factor, insulin, hydrocortisone, transferrin,
oestrogen or progesterone did not improve the proliferation
and viability of the culture, and the use of collagen-coated
flasks did not benefit the adhesion or the growth of the cells
(results not shown).
The insertion of the 1 h panning step between the prepara-
tion of the cell suspension and its final culture led to a
substantial reduction in the percentage of F15-positive
stromal cells (Table II, no. 1). In the final preparation, glands
and single cells adhered to the flask surface; cells appeared to
spread out from the glands and form round growing colonies
in an epithelial monolayer surrounded by scattered stromal
cells. After 10 days in culture the epithelial colonies no longer
increased in size, while fibroblasts started to grow and cover
the surface of the flask. After 2-3 weeks, the epithelial
colonies started to senesce and eventually died, and the flask
remained covered with fibroblasts as confirmed by
immunocytochemistry.
During culture, treatment with the low-Ca' medium was
used occasionally to reduce fibroblast overgrowth (Table II,
no. 2). We attempted to passage the primary epithelial cell
cultures using trypsin/EDTA. The epithelial cells detached
from the flask only after 15 min treatment with double con-
centration of trypsin/EDTA and then failed to readhere after
resuspension in culture medium (Table II, nos. 3 and 4). It
was therefore necessary to plate the cells in the required
experimental flasks or wells at the establishment of the
primary culture.
Table II Cultured cells were stained with LP34 and F15 antibodies
in order to estimate the proportion of epithelial and stromal cells in
the cultures. The proportion of antigen-positive cells, assessed by
light microscopy, is expressed as a percentage of total cells counted
in several low-power fields
Type of tissuel LP34 F15
preparation (%) (%)
1. Proliferative + secretory
Before panning step 30 60
After panning step 60 40
2. Menopausal 30 50
Low-Ca2l medium 60 5
3. Secretory
Before passage 70 20
After passage 15 55
4. Cancer after passage 0 30
5. Normal 60-90 0-40
6. Cancerous 80-90 10-20
7. Hyperplasia 20-90 10-70
Immunocytochemistry
Cytocentrifuge preparations of cells enabled quantitation of
the proportion of positively staining cells, whereas cells
grown on slides maintained their cytoskeletal structure,
confiming the morphological observations of the epithelial
nature of the cultures (Figure 5).
The proportion of the cytokeratin-expressing epithelial
cells varied between cultures depending upon the nature of
the tissue from which they derived and the method used for
culture (Table II). In five out of nine specimens of normal
endometrium that were cultured and tested, 60-90% of the
cells expressed cytokeratins, the remainder staining with F15.
In three out of three malignant cell cultures tested, 80-90%
of the cells were cytokeratin positive and 10-20% expressed
PLAP. There was no detectable P-hCG expression. In com-
parison, Ishikawa cells were found to be strongly cytokeratin.
PLAP and P-hCG positive, but PP14 negative.
Protein assays
The culture supernatants were assayed for PP14, PLAP, CA-
125 and total P-hCG (Table III).
PP14 was found in 18/22 culture supernatants of normal
proliferative, secretory and perimenopausal tissues. It was
not detected in the supernatants from late menopausal and
malignant tissues or in the supernatants from the Ishikawa
cell line (Table III).MARKER ANTIGENS IN ENDOMETRIUM 1013
Figure 5 Cells from normal endometrial culture reveal their




Table HI Supernatants from primary cultures and cell line cultures
were collected after 4 days, stored at - 20°C and assayed for the
presence of PP14, PLAP, P-hCG and CA125
Positivel
Tissue total % Concentration
(a) PP14 (igI-)
Pre-/perimenopausal 17/19 89 25-500
Post-menopausal 0/1 0 <5
Hyperplastic 2/2 100 9-32
Malignant 0/6 0 <5
Ishikawa -a 0 <5
(b) PLAP (IU 1-')
Pre-/post-menopausal 0/10 0 <1
Hyperplastic 1/2 50 3-6
Malignant 10/14 67 1.5-20
Ishikawa -a 100 4-6
(c) Ji-hCG (IU 1-')
Pre-/post-menopausal 0/2 0 <25
Hyperplastic 1/2 50 50
Malignant 1/5 20 118
Ishikawa -a 100 340-560
(d) CA125 (IU ml-')
Pre-/post-menopausal 2/2 100 53-341
Malignant 6/6 100 34-450
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Figure 6 The production of PP14 with respect to time in culture
by individual primary cultures of endometrium. Assay was by a
radioimmunometric method, using supernatants at 2 day inter-
vals. A, Mid-cycle; A, perimenopausal; 0, proliferative; *,
secretory endometrium.
PP14 levels (25-500pg 1`) varied according to the men-
strual status of the tissue (Figure 6) and were higher in the
first 5 days of culture. Serial samples from four cultures
showed a rapid decline in PP14 secretion, so that by 14 days
no more could be detected.
PLAP was found in 10/14 culture supernatants from
endometrial cancers (13 post- and one premenopausal), at a
level of 1.5-20 IU 1-' for up to 9 days of culture, but from
none of the ten normal endometrial cultures [derived from
premenopausal from all stages of the cycle (n = 6), peri-
(n = 3) and post-menopausal (n = 1) tissues] (Table III).
PLAP was detected however in one of two culture super-
natants from hyperplastic endometrium (3-6 IU I1) and
from the Ishikawa cell line (4-6IUI1).
CA-125 was detected in two out of two supernatants from
cell cultures derived from normal endometrium
(53-341 U ml-') and was also present in six out of six
supernatants from endometrial cancers (34-450 U ml-',
median 234Uml-'). In contrast, cultures of stromal cells
and the Ishikawa cell line secreted CA-125 into the culture
supernatant in very small amounts (17 and 7 U ml1 respec-
tively).
No P-hCG could be found in the supernatant from normal
cells, but it was present in low levels in the supernatant from
one out of five malignant cell cultures (118 IU 1-) and in the
supernatant from the one hyperplastic cell culture (50 IU 1`),
which also produced PLAP (5 IU 1`). The Ishikawa cell
supernatant was consistently and strongly positive for P-hCG
(340-560 IU 1-l).
Discussion
Normal and malignant endometrial epithelial cells have been
established in short-term tissue culture and characterised as
expressing many of the features of their parent tissues. We
have developed a method for the selection of the epithelial
cells, which relies upon the more rapidly adherent nature of
the stromal cells, to produce highly enriched epithelial cul-
tures. We chose to do this rather than to separate the glands
by sieving (Satyasrawoop et al., 1979) because we wished to
culture cells from malignant tissues that frequently do not
retain a glandular structure on disaggregation. Immuno-
chemistry on tissue biopsies and cultured cells showed that
the cells maintain their in vivo characteristics after they have
been cultured in the laboratory.
PP14 is found in the serum of premenopausal women,
reaching peak levels in late luteal phase or following embryo
implantation (Wood et al., 1989; Olajide & Chard, 1992).
Many sites in the genital tract have been suggested as the
source of PP14 in the serum, but we have found the normal
endometrial glandular epithelium to be a major site of PP14
synthesis and secretion in vitro. PP14 may prove to be a
useful clinical marker of the presence of mature secretory
endometrium. In agreement with previously reported
immunohistochemistry findings (Wood et al., 1988), PP14
was not detected in endometrial cancer, and cultured malig-
nant cells did not secrete PP14, even though some of the
patients had been on progesterone treatment, which may
stimulate PP14 secretion (Wood et al., 1988).
Low levels of PLAP expression have been described in
non-malignant tissues such as cervix, lung, testis and thymus
(Goldstein et al., 1982; McLaughlin et al., 1984), and
elevated serum levels have been found in patients with testis,
ovary, cervix and endometrial cancers (Nathanson & Fish-
man, 1971). PLAP was readily detectable in endometrial
cancer frozen sections and cell cultures, where it could be
localised to the epithelial cells, but not in the normal tissues.
PLAP was secreted in the culture supernatant for as long as
there were viable epithelial cells, and declined with the de-
cline in cell number.
CA-125 has been previously suggested as a tissue and
serum marker for endometrial cancer, and we were therefore
interested to correlate its expression with that of PLAP.
CA-125 was secreted by both normal and malignant endo-
_ .
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metrial cells in the small number of specimens examined,
although the endometrial cancers secreted 5-10 times as
much as the normal endometrium. Whether PLAP secretion
is completely coincident with CA-125, as was observed in
three of our cultures, or can increase the detectable range of
tumours or the stage at which the cancers can be detected,
must await further clinical studies.
We did not detect any P-hCG production in the normal
endometrium and found it only rarely in endometrial cancer,
in a similar manner to its ectopic production in other
cancers, such as of lung and bladder (Braunstein, 1983; Iles
et al., 1987). One out of the two specimens of simple
endometrial hyperplasia was both PLAP and ,B-hCG positive,
suggesting that secretion of these proteins needs to be studied
further in endometrial hyperplasia to determine whether it is
induced at an early stage of proliferation or malignant trans-
formation.
Both PLAP and P-hCG were secreted by the Ishikawa cell
line, the control of which is the subject of further study.
Comparison of the results from the primary endometrial
cancer cultures and the established endometrial adenocar-
cinoma cell line showed marked differences in P-hCG and
CA-125 secretion, emphasising our continuing need for a
primary culture system that represents as closely as possible
the in vivo situation.
In conclusion, normal endometrial epithelium expressed
PP14 but not PLAP, while endometrial cancer cells were
shown to produce PLAP but not PP14. These qualitative
differences, evident on both the immunohistology of frozen
sections and the immunochemistry of the cells and their
supernatants, were in contrast to the quantitative differences
in expression of CA-125, which was present in all cultures.
PLAP secretion has proved to be a marker for endometrial
cancer cells in culture, which will enable further investigation
of the factors controlling their proliferation and differenti-
ation in vitro. PLAP may prove to be of greater use than the
more widely distributed CA-125 as a clinical marker for the
diagnosis and monitoring of patients with endometrial
cancer.
We wish to thank Mrs P. Perkis for technical assistance, our
gynaecological colleagues and especially Mr J. Norman-Taylor for
tissue collection, and the Association for International Cancer
Research for financial support.
References
BAST, R.C., FEENEY, R., LAZARUS, H., NADLER, L.M., COLVIN, R.B.
& KNAPP, B.C. (1981). Reactivity of a monoclonal antibody with
human ovarian carcinoma. J. Clin. Invest., 68, 1331-1337.
BELL, S.C., PATEL, S., HALES, M.W., KIRWAN, P.H. & DRIFE, J.O.
(1985). Immunochemical detection and characterization
pregnancy-associated endometrial alpha-I and alpha-2 globulins
secreted by human endometrium and decidua. J. Reprod. Fertil.,
74, 261-270.
BOLTON, A.E., CHAPMAN, M.G., STOKER, R.J., ANDREW, C.E.,
WASS, D. & BOHN, H. (1983). The radioimmunoassay of human
placental protein 14 (PP14). Clin. Chim. Acta, 135, 283-291.
BRAUNSTEIN, G.D. (1983). HCG expression in trophoblastic and
non-trophoblastic tumours. In Oncodevelopmental Markers:
Biologic, Diagnostic and Monitoring Aspects, Braunstein, G.D.
(ed.), pp. 351-371. Academic Press: New York.
CREASMAN, W.T. (1991). Estrogen replacement therapy: is
previously treated cancer a contraindication? Obstet. Gynaecol.,
77, 308-312.
FISHMAN, W.H., INGLIS, N.R., STOLBACH, L.L. & KRANT, M.J.
(1968). A serum alkaline phosphatase isoenzyme of human neo-
plastic cell origin. Cancer Res., 28, 150-154.
GOLDSTEIN, D.J., ROGERS, C. & HARRIS, H. (1982). A search for
trace expression of placental alkaline phosphatase in non-
malignant human tissues: demonstration ofits occurrence in lung,
cervix, testis and thymus. Clin. Chim. Acta, 125, 63-75.
HOWELL, R.J., OLAJIDE, F., TEISNER, B., GRUDZINSKAS, J.G. &
CHARD, T. (1989). Circulating levels of placental protein 14 and
progesterone following Mifepristone (RU 38486) and Gemeprost
for termination of first trimester pregnancy. Fertil. Steril., 52,
66-68.
ILES, R.K. & CHARD, T. (1989). Immunochemical analysis of the
human chorionic gonadotrophin-like material secreted by 'nor-
mal' and neoplastic urothelial cells. J. Mol. Endocrinol., 2,
107-112.
ILES, R.K., OLIVER, R.T.D., KITAU, M.. WALKER, C. & CHARD, T.
(1987). In vitro secretion of human chorionic gonadotrophin by
bladder tumour cells. Br. J. Cancer, 55, 623-626.
ILES, R.K., IND, T.E.J. & CHARD, T. (1994). Production of placental
alkaline phosphatase (PLAP) and PLAP-like material by
epithelial germ cells and non-germ cell tumours in vitro. Br. J.
Cancer (in press).
JULKUNEN, M., RUTANEN, E.M., KOSKIMIES, A., RANTA, T.,
BOHN, H., SEPPALA, M. (1985). Distribution of placental protein
14 in tissues and body fluids during pregnancy. Br. J. Obstet.
Gynaecol., 92, 1145-1151.
MCLAUGHLIN, P.J., TRAVERS, P.J., MCDICKEN, I.W. & JOHNSON,
P.M. (1984). Demonstration of placental and placental-like
alkaline phosphatase in non-malignant human tissue extracts
using monoclonal antibodies in an enzyme immunoassay. Clin.
Chim. Acta, 137, 341-348.
NATHANSON, L. & FISHMAN, W.H. (1971). New observations on the
Regan isoenzyme of alkaline phosphatase in cancer patients.
Cancer, 27, 1388-1397.
NISHIDA, M., KASAHARA, K., KANEKO, M., IWASAKI, H. &
HAYASHI, K. (1985). Establishment of a new human adenocar-
cinoma cell line, Ishikawa cells, containing oestrogen and pro-
gesterone receptors. Acta Obstet. Gynecol. Jpn, 37, 1103-1111.
OLAJIDE, F. & CHARD, T. (1992). Biological and clinical significance
of the endometrial protein PP14 in reproductive endocrinology.
Obstet. Gynaecol. Survey, 47, 252-257.
SATYASWAROOP, P.G., BRESSLER, B.S., DE LA PENNA, M.M. &
GURPIDE, E. (1979). Isolation and culture of human endometiral
glands. J. Clin. Endocrinol. Metab., 48, 639-641.
TRAVERS, P. & BODMER, W. (1984). Preparation and characteriza-
tion of monoclonal antibodies against placental alkaline phos-
phatase and other human trophoblast associated determinants.
Int. J. Cancer, 33, 633-641.
UZEILY, B., LEWIN, A., BRUFMAN, G., DOREMBUS, D. & MOR-
YOSEF, S. (1993). The effect of tamoxifen on the endometrium.
Breast Cancer Res. Treat., 26, 101-105.
WAHREN, B., HOLMGREN, P.A. & STIGBRAND, T. (1979). Placental
alkaline phosphatase, alpha fetoprotein and carcinoembryonic
antigen in testicular tumours. Int. J. Cancer, 24, 749-753.
WOOD, P.L., WAITES, G.T., MACVICAR, J., DAVINSON, A.C.,
WALKER, R.A., BELL, S.C. (1988). Immunohistological localiza-
tion of pregnancy-associated endometrial alpha2-globulin
(alpha2-PEG) in endometrial adenocarcinoma and effect of
medroxy-progesterone acetate. Br. J. Obstet. Gynaecol., 95,
1292-1298.
WOOD, P.L., WALKER, R.A. & BELL, S.C. (1989). Serum levels of
pregnancy associated endometrial alpha2-globulin (alpha2-PEG)
during normal menstrual and combined oral contraceptive cycles
and relationship to immunohistological localization. Hum. Re-
prod., 4, 140-146.